Stepping up its efforts to push products into the burgeoning molecular diagnostics market, Invitrogen last week licensed its Lux reagent technology to Prodesse, a Wisconsin-based developer of multiplex PCR-based diagnostic tests.
The alliance is the latest in a series of actions taken by Invitrogen to further develop a variety of technologies acquired during its 2004-2005 buying spree for the molecular diagnostics field. The pact also furthers Invitrogen’s plans to greatly expand its OEM business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.